Corrigendum to "Elevated amyloid beta peptides and total tau in cerebrospinal fluid in individuals with Creatine transporter deficiency".

Rahhal S ¹,

Farmer C ²,

Thurm A ²,

Wassif CA ¹,

Affiliations

1. Division of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (NIH), Bethesda, MD, USA.
Authors
Rahhal S¹
Wassif CA¹
Cawley NX¹
Perreault J¹
Dang Do A¹
Bianconi S¹
Hannah-Shmouni F¹
Porter FD¹
(8 authors)
2. Neurodevelopmental and Behavioral Phenotyping Service, National Institute of Mental Health, National Institutes of Health (NIH), Bethesda, MD, USA.
Authors
Farmer C²
Thurm A²
(2 authors)
3. Center for Autism Research, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Authors
Guthrie W³
Cubit LS³
Miller JS³
(3 authors)
4. Department of Molecular & Human Genetics, Baylor College of Medicine & Texas Children's Hospital, USA.
Authors
Sutton VR⁴
(1 author)
5. Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.
Authors
Koeberl D⁵
(1 author)

ORCIDs linked to this article

Hannah-Shmouni, MD FRCPC F | 0000-0001-6829-6205

Molecular Genetics and Metabolism Reports, 09 Oct 2023, 37:101013
https://doi.org/10.1016/j.ymgmr.2023.101013 PMID: 38053934 PMCID: PMC10694737

Free full text in Europe PMC

This corrects "Elevated amyloid beta peptides and total tau in cerebrospinal fluid in individuals with Creatine transporter deficiency." Mol Genet Metab Rep. 2023 Aug 21;37:101001.

Abstract

[This corrects the article DOI: 10.1016/j.ymgmr.2023.101001.].

Free full text

Mol Genet Metab Rep. 2023 Dec; 37: 101013.

Published online 2023 Oct 9. https://doi.org/10.1016/j.ymgmr.2023.101013

PMCID: PMC10694737

PMID: 38053934

Corrigendum to “Elevated amyloid beta peptides and total tau in cerebrospinal fluid in individuals with Creatine transporter deficiency”

Samar Rahhal,^a, Cristan Farmer,^b Audrey Thurm,^b Christopher A. Wassif,^a Niamh X. Cawley,^a John Perreault,^a An Dang Do,^a Simona Bianconi,^a Fady Hannah-Shmouni,^a Whitney Guthrie,^c,^d Laura S. Cubit,^c Judith S. Miller,^c,^d V. Reid Sutton,^e Dwight Koeberl,^f and Forbes D. Porter^a

Samar Rahhal

^aDivision of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (NIH), Bethesda, MD, USA

Find articles by Samar Rahhal

Cristan Farmer

^bNeurodevelopmental and Behavioral Phenotyping Service, National Institute of Mental Health, National Institutes of Health (NIH), Bethesda, MD, USA

Find articles by Cristan Farmer

Audrey Thurm

^bNeurodevelopmental and Behavioral Phenotyping Service, National Institute of Mental Health, National Institutes of Health (NIH), Bethesda, MD, USA

Find articles by Audrey Thurm

Christopher A. Wassif

^aDivision of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (NIH), Bethesda, MD, USA

Find articles by Christopher A. Wassif

Niamh X. Cawley

^aDivision of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (NIH), Bethesda, MD, USA

Find articles by Niamh X. Cawley

John Perreault

^aDivision of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (NIH), Bethesda, MD, USA

Find articles by John Perreault

An Dang Do

^aDivision of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (NIH), Bethesda, MD, USA

Find articles by An Dang Do

Simona Bianconi

^aDivision of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (NIH), Bethesda, MD, USA

Find articles by Simona Bianconi

Fady Hannah-Shmouni

^aDivision of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (NIH), Bethesda, MD, USA

Find articles by Fady Hannah-Shmouni

Whitney Guthrie

^cCenter for Autism Research, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

^dDivision of Developmental and Behavioral Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Find articles by Whitney Guthrie

Laura S. Cubit

^cCenter for Autism Research, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Find articles by Laura S. Cubit

Judith S. Miller

^cCenter for Autism Research, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

^dDivision of Developmental and Behavioral Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Find articles by Judith S. Miller

V. Reid Sutton

^eDepartment of Molecular & Human Genetics, Baylor College of Medicine & Texas Children's Hospital, USA

Find articles by V. Reid Sutton

Dwight Koeberl

^fDepartment of Pediatrics, Duke University School of Medicine, Durham, NC, USA

Find articles by Dwight Koeberl

Forbes D. Porter

^aDivision of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (NIH), Bethesda, MD, USA

Find articles by Forbes D. Porter

Author information Copyright and License information Disclaimer

This corrects the article "Elevated amyloid beta peptides and total tau in cerebrospinal fluid in individuals with Creatine transporter deficiency" in volume 37, 101001.

This article has been cited by other articles in PMC.

We would like to make a correction to Table 1.

Table 1

CTD participant demographics, phenotype, and CSF biomarker levels. NW = no words; SW = single words; P = Phrases (i.e., uses multiple words together but not fluent speech). ABC = Vineland Adaptive Behavior Composite Score (population mean = 100, SD = 15). NVDQ = nonverbal developmental quotient from Mullen Scales of Early Learning (except where indicated). ^aCognitive test was a Weschler Abbreviated Scale of Intelligence.

ID	Sex	Age (yrs)	Seizure	Baseline Verbal Status	Baseline ABC	Baseline NVDQ	Tau (pg/ml)	Aβ42 (pg/ml)	Aβ40 (pg/ml)	Aβ42/ Aβ40	Pathological Variant	Protein Change
CD00028	M	7	no	NW	33	30.3	338.9	1560.6	17,808	0.088	c.1145C > T	p.P328L
CD00005	M	6.2	yes	SW	66	55^a	139.3	442.9	5491.3	0.081	c912 + 36_913-18del35	Intron 5: 35 bp deletion
CD00004	M	10.2	yes	P	69	56 ^a	135	476.1	5961.4	0.080	c.859delC	p.1286wfsx22
CD00019	M	3.2	no	SW	65	47.1	300.6	1379.8	16,262.3	0.085	293 bp deletion of exon encompassing part of exon 10 and entire exon 11	N/A
CD00012	M	14.3	yes	P	36	51 ^a	224.1	941.1	11,098.5	0.085	c.1146_1150dup	p.L384RfxS14
CD00003	M	6.9	yes	SW	50	42	168.1	712.4	9538.1	0.075	c.321_323delCTT	p.F107del
CD00027	M	10.4	no	P	52	45 ^a	138.9	661.9	7801.3	0.085	unavailable	unavailable
CD00014	M	4.2	no	SW	62	61.9	202	964.1	11,004.9	0.088	c.1222_1224delTTC	p.F408del
CD00002	M	11	yes	NW	31	23.7	287.6	1278	14,226.2	0.090	c.1667G > A transition	p.Trp556X
CD00008	M	13.4	yes	NW	20	12.1	158	110.6	1459	0.076	c.1554G > A	p.W518X
CD00006	M	3.6	yes	NW	65	45.4	131	550.6	7032.8	0.078	c912 + 36_913-18del35	Intron 5: 35 bp deletion
CD00013	M	3.2	no	NW	55	23.2	195.3	982.3	10,991.8	0.089	c.1396G > A	p.G466R

The authors would like to apologize for any inconvenience caused.

Articles from Molecular Genetics and Metabolism Reports are provided here courtesy of Elsevier

Full text links

Read article at publisher's site: https://doi.org/10.1016/j.ymgmr.2023.101013

Citations & impact

Impact metrics

Citation

Jump to Citations

Alternative metrics

Altmetric item for https://www.altmetric.com/details/157320487

Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/157320487

Article citations

Dodecyl creatine ester therapy: from promise to reality.
Mabondzo A, van de Kamp J, Mercimek-Andrews S
Cell Mol Life Sci, 81(1):186, 17 Apr 2024
Cited by: 0 articles | PMID: 38632116 | PMCID: PMC11024018
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

Search life-sciences literature (45,103,589 articles, preprints and more)

Corrigendum to "Elevated amyloid beta peptides and total tau in cerebrospinal fluid in individuals with Creatine transporter deficiency".

Affiliations

ORCIDs linked to this article

Abstract

Free full text

Corrigendum to “Elevated amyloid beta peptides and total tau in cerebrospinal fluid in individuals with Creatine transporter deficiency”

Samar Rahhal

Cristan Farmer

Audrey Thurm

Christopher A. Wassif

Niamh X. Cawley

John Perreault

An Dang Do

Simona Bianconi

Fady Hannah-Shmouni

Whitney Guthrie

Laura S. Cubit

Judith S. Miller

V. Reid Sutton

Dwight Koeberl

Forbes D. Porter

Table 1

Full text links

Citations & impact

Impact metrics

Alternative metrics

Article citations

Dodecyl creatine ester therapy: from promise to reality.

Similar Articles

Elevated amyloid beta peptides and total tau in cerebrospinal fluid in individuals with Creatine transporter deficiency.

Corrigendum: Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aß_1-42, and Tau Proteins in Elderly Patients With Mild Cognitive Impairment.

Corrigendum to "First contiguous gene deletion causing biotinidase deficiency: The enzyme deficiency in three Sri Lankan children" [Mol. Genet. Metab. Rep. 2 (2016) 81-84].

Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid.

Partnerships & funding

Search life-sciences literature (45,103,589 articles, preprints and more)

Corrigendum to "Elevated amyloid beta peptides and total tau in cerebrospinal fluid in individuals with Creatine transporter deficiency".

Author information

Affiliations

ORCIDs linked to this article

Abstract

Free full text

Corrigendum to “Elevated amyloid beta peptides and total tau in cerebrospinal fluid in individuals with Creatine transporter deficiency”

Samar Rahhal

Cristan Farmer

Audrey Thurm

Christopher A. Wassif

Niamh X. Cawley

John Perreault

An Dang Do

Simona Bianconi

Fady Hannah-Shmouni

Whitney Guthrie

Laura S. Cubit

Judith S. Miller

V. Reid Sutton

Dwight Koeberl

Forbes D. Porter

Table 1

Full text links

Citations & impact

Impact metrics

Alternative metrics

Article citations

Dodecyl creatine ester therapy: from promise to reality.

Similar Articles

Elevated amyloid beta peptides and total tau in cerebrospinal fluid in individuals with Creatine transporter deficiency.

Corrigendum: Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aß1-42, and Tau Proteins in Elderly Patients With Mild Cognitive Impairment.

Corrigendum to "First contiguous gene deletion causing biotinidase deficiency: The enzyme deficiency in three Sri Lankan children" [Mol. Genet. Metab. Rep. 2 (2016) 81-84].

Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid.

Partnerships & funding

Corrigendum: Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aß_1-42, and Tau Proteins in Elderly Patients With Mild Cognitive Impairment.